FRANKFURT, Aug 26 (Reuters) - A committee advising the U.S. Food and Drug Administration (FDA) will discuss Boehringer Ingelheim’s Pradaxa pill on Sept. 20, raising the prospect of a speedy market entry for the first drug in a new class of blood thinners.
